Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial

Pasireotide Acromegaly Study Group; S Petersenn; J Schopohl; A Barkan; P Mohideen; A Colao; R Abs; A Buchelt; Y-Y Ho; K Hu; Andrew Farrall; S Melmed; B M K Biller

doi:10.1210/jc.2009-2272

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial

Pasireotide Acromegaly Study Group, S Petersenn, J Schopohl, A Barkan, P Mohideen, A Colao, R Abs, A Buchelt, Y-Y Ho, K Hu, Andrew Farrall, S Melmed, B M K Biller

Research output: Contribution to journal › Article › peer-review

Abstract

Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes sst(1-3) and sst(5). Because most GH-secreting pituitary adenomas express sst(2) and sst(5), pasireotide has the potential to be more effective than the sst(2)-preferential somatostatin analogs octreotide and lanreotide.

Original language	English
Pages (from-to)	2781-9
Number of pages	9
Journal	The Journal of Clinical Endocrinology & Metabolism (JCEM)
Volume	95
Issue number	6
DOIs	https://doi.org/10.1210/jc.2009-2272
Publication status	Published - Jun 2010

Keywords

Acromegaly
Adolescent
Adult
Aged
Aged, 80 and over
Blood Glucose
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Endpoint Determination
Female
Human Growth Hormone
Humans
Insulin-Like Growth Factor I
Magnetic Resonance Imaging
Male
Middle Aged
Octreotide
Pituitary Neoplasms
Somatostatin
Young Adult

Access to Document

10.1210/jc.2009-2272

Cite this

Pasireotide Acromegaly Study Group, Petersenn, S., Schopohl, J., Barkan, A., Mohideen, P., Colao, A., Abs, R., Buchelt, A., Ho, Y-Y., Hu, K., Farrall, A., Melmed, S., & Biller, B. M. K. (2010). Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. The Journal of Clinical Endocrinology & Metabolism (JCEM), 95(6), 2781-9. https://doi.org/10.1210/jc.2009-2272

@article{31834f6a7a5049318fcdc0f2b8da18ae,

title = "Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial",

abstract = "Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes sst(1-3) and sst(5). Because most GH-secreting pituitary adenomas express sst(2) and sst(5), pasireotide has the potential to be more effective than the sst(2)-preferential somatostatin analogs octreotide and lanreotide.",

keywords = "Acromegaly, Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Endpoint Determination, Female, Human Growth Hormone, Humans, Insulin-Like Growth Factor I, Magnetic Resonance Imaging, Male, Middle Aged, Octreotide, Pituitary Neoplasms, Somatostatin, Young Adult",

author = "{Pasireotide Acromegaly Study Group} and S Petersenn and J Schopohl and A Barkan and P Mohideen and A Colao and R Abs and A Buchelt and Y-Y Ho and K Hu and Andrew Farrall and S Melmed and Biller, {B M K}",

year = "2010",

month = jun,

doi = "10.1210/jc.2009-2272",

language = "English",

volume = "95",

pages = "2781--9",

journal = "The Journal of Clinical Endocrinology & Metabolism (JCEM)",

issn = "0021-972X",

publisher = "Oxford University Press",

number = "6",

}

Pasireotide Acromegaly Study Group, Petersenn, S, Schopohl, J, Barkan, A, Mohideen, P, Colao, A, Abs, R, Buchelt, A, Ho, Y-Y, Hu, K, Farrall, A, Melmed, S & Biller, BMK 2010, 'Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial', The Journal of Clinical Endocrinology & Metabolism (JCEM), vol. 95, no. 6, pp. 2781-9. https://doi.org/10.1210/jc.2009-2272

TY - JOUR

T1 - Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly

T2 - a randomized, multicenter, phase II trial

AU - Pasireotide Acromegaly Study Group

AU - Petersenn, S

AU - Schopohl, J

AU - Barkan, A

AU - Mohideen, P

AU - Colao, A

AU - Abs, R

AU - Buchelt, A

AU - Ho, Y-Y

AU - Hu, K

AU - Farrall, Andrew

AU - Melmed, S

AU - Biller, B M K

PY - 2010/6

Y1 - 2010/6

N2 - Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes sst(1-3) and sst(5). Because most GH-secreting pituitary adenomas express sst(2) and sst(5), pasireotide has the potential to be more effective than the sst(2)-preferential somatostatin analogs octreotide and lanreotide.

AB - Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes sst(1-3) and sst(5). Because most GH-secreting pituitary adenomas express sst(2) and sst(5), pasireotide has the potential to be more effective than the sst(2)-preferential somatostatin analogs octreotide and lanreotide.

KW - Acromegaly

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Blood Glucose

KW - Cross-Over Studies

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Endpoint Determination

KW - Female

KW - Human Growth Hormone

KW - Humans

KW - Insulin-Like Growth Factor I

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Octreotide

KW - Pituitary Neoplasms

KW - Somatostatin

KW - Young Adult

U2 - 10.1210/jc.2009-2272

DO - 10.1210/jc.2009-2272

M3 - Article

C2 - 20410233

VL - 95

SP - 2781

EP - 2789

JO - The Journal of Clinical Endocrinology & Metabolism (JCEM)

JF - The Journal of Clinical Endocrinology & Metabolism (JCEM)

SN - 0021-972X

IS - 6

ER -

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this